## **EUPATI FELLOWS**

#### COHORTS 1-6





The EUPATI **Patient Expert Training Programme** is a training programme about the medicines' development process that covers the entire lifecycle of medicines(R&D).

The Programme was originally designed for patients and patient representatives. Today, while is still **mainly** addressed to patients and patient representatives, it is open to all individuals interested in medicines R&D and patient engagement.

The Programme consists of **6 online modules and 2 training events of 4 days each**. Completing the entire program usually takes between 12 and 14 months. Each **cohort** is a group of trainees who have completed the program over the same period of time and have participated in the events together.

# The selection process per cohort:



Rigorous application and selection process (to ensure wide geographical and disease-area representation but also exclude representatives from any other stakeholder group).



Non-selective approach that opens up the programme to a limited number of other stakeholders representatives

The following are the characteristics of the trainees who have completed the Patient Expert Training Programme from **Cohort 1 to 6 (2015-2023)** 




GENDER REPRESENTATION




# DISEASE AREA REPRESENTATION

Cancer and rare diseases are most common conditions among the Fellows



#### **TYPES OF CANCER**



#### **RARE DISEASES**

Autoinflammatory disease
COAT's
Congenital Disorder of
Glycosylation
Cystic Fibrosis
Duchenne Muscular Dystrophy
Ehlers-Danlos syndrome
Epidermolysis bullosa
Fibrodysplasia ossificans
progressiva
Friedreich's ataxia
Gaucher disease
GNE Myopathy

Addison's disease

Hereditary hemorrhagic
telangiectasia (HHT)
Muscular dystrophy
Osteonecrosis of the jaw
Pitt Hopkins Syndrome
Propriospinal myoclonus
Rare genetic disease
Rare liver disease
Rare neuromuscular disease
Rare optic diseases
Rare Paediatric disease
Sanfilippo Syndrome
Spinal Muscular Atrophy
Trisomy 8
Usher Syndrome

22,9%

19.0%

Duchenne and Cystic Fibrosis are the most common rare diseases with 8 and 7 trainees respectively.

## STAKEHOLDER REPRESENTATION

**Patients** 



**92**%

Patient, caregiver or patient representative

6% have also a role in Industry or Academia

#### Other stakeholders



Industry representative



Academic/Researcher



Healthcare professional



Other









**Note**: Other Stakeholders were only introduced from Cohort 5